TAB1 (TAK1-Binding Protein 1) is a critical adaptor protein in the TGF-β-activated kinase 1 (TAK1) signaling pathway. It plays a central role in regulating inflammatory responses, cell survival, and stress-induced signaling cascades that are implicated in neurodegenerative diseases.
TAB1 is a 504-amino acid protein with a molecular weight of approximately 55 kDa. The protein contains several functional domains:
- N-terminal domain: Interacts with TAK1 and mediates complex formation
- Central region: Contains binding sites for TAB2/TAB3
- C-terminal domain: Involved in protein-protein interactions
¶ Function and Signaling
TAB1 forms a heterotrimeric complex with TAK1 (MAP3K7) and TAB2/TAB3, which is essential for TAK1 activation. This complex serves as a key node in multiple signaling pathways:
- NF-κB signaling: TAB1-TAK1 complex activates the IKK complex, leading to NF-κB nuclear translocation and inflammatory gene expression
- JNK/AP-1 pathway: TAK1 activation leads to JNK phosphorylation and AP-1 transcription factor activation
- p38 MAPK pathway: The TAB1-TAK1 complex also regulates p38 MAPK signaling
TAB1 is a central regulator of neuroinflammation through its role in:
- Cytokine production: Facilitates TNF-α, IL-1β, and IL-6 production in microglia
- NLRP3 inflammasome: Regulates inflammasome activation in neurodegenerative contexts
- Microglial activation: Modulates microglial phenotypic changes toward a pro-inflammatory state
In AD, TAB1-mediated signaling contributes to:
- Chronic neuroinflammation: Enhanced TAK1 activation leads to sustained NF-κB activity in microglia surrounding amyloid plaques
- Tau pathology: TAB1-TAK1 signaling intersects with tau phosphorylation pathways through GSK3β modulation
- Blood-brain barrier dysfunction: Inflammatory signaling via TAB1 affects endothelial cell function
TAB1 signaling in PD is associated with:
- Dopaminergic neuron survival: TAK1 activation can be both neuroprotective and neurotoxic depending on context
- Neuroinflammation: Elevated TAB1 expression in substantia nigra of PD patients
- α-Synuclein pathology: Cross-talk between TAK1 signaling and α-synuclein (SNCA) aggregation
TAB1 dysregulation has been implicated in:
- Motor neuron degeneration through enhanced inflammatory signaling
- Glial cell activation and neuroinflammation
- Protein aggregation pathways
- TAK1 inhibitors: While not specific to TAB1, TAK1 inhibitors (e.g., 5Z-7-Oxozeaenol) can modulate TAB1-TAK1 signaling
- NF-κB pathway modulators: Downstream inhibitors of TAB1-TAK1-NF-κB axis
- Microglial-specific modulation: Targeting TAB1 in microglia to reduce harmful inflammation while preserving protective functions
- Blood-brain barrier penetration: Developing centrally-acting TAK1/TAB1 modulators
| Partner |
Interaction Type |
Function |
| TAK1 (MAP3K7) |
Direct binding |
Catalytic complex formation |
| TAB2 |
Direct binding |
Complex stabilization |
| TAB3 |
Direct binding |
Alternative complex formation |
| IKKβ |
Phosphorylation target |
NF-κB activation |
| MKK7 |
Phosphorylation target |
JNK pathway activation |
TAB1 is widely expressed in the central nervous system:
- Neurons: Moderate expression in cortical and hippocampal neurons
- Astrocytes: High expression in reactive astrocytes
- Microglia: Elevated expression in activated microglia
- Oligodendrocytes: Lower baseline expression